^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer

Published date:
07/06/2023
Excerpt:
A single-center retrospective study was conducted to evaluate the influence of PD-L1 expression on the efficacy of EGFR-TKIs for NSCLC patients with EGFR mutation....Higher PD-L1 expression was associated with shorter PFS.
DOI:
10.1111/1759-7714.15021
Evidence Level:
Resistant: C3 – Early Trials
Title:

A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs

Published date:
03/20/2023
Excerpt:
The median progression-free survival (mPFS) of patients with PD-L1 negative expression, low expression and high expression who received first generation EGFR-TKIs treatment were 12.4 months, 10.5 months and 3.7 months, respectively, with significant statistical difference (P<0.0001)....The expression level of PD-L1 in advanced EGFR positive NSCLC patients was significantly correlated with the pathomorphology classification of cancer cells. The efficacy of EGFR-TKIs in patients with PD-L1 overexpression NSCLC was significantly poor.
DOI:
10.3779/j.issn.1009-3419.2023.101.09
Evidence Level:
Resistant: C3 – Early Trials
Title:

Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis

Published date:
05/08/2021
Excerpt:
Patients with high PD-L1 expression was associated with poorer PFS (HR = 1.90; 95% CI = 1.16-3.10; P = 0.011)...The result of this meta-analysis suggested that PD-L1 expression might be a predictive biomarker for EGFR-mutant non-small cell lung cancer treated with EGFR-TKIs.
DOI:
10.1186/s12957-021-02254-x